Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Gains from Investment Securities (2017 - 2025)

Dare Bioscience (DARE) has disclosed Gains from Investment Securities for 9 consecutive years, with $958315.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Gains from Investment Securities fell 25.79% year-over-year to $958315.0, compared with a TTM value of -$41685.0 through Sep 2025, down 106.03%, and an annual FY2024 reading of $358315.0, down 72.25% over the prior year.
  • Gains from Investment Securities was $958315.0 for Q4 2024 at Dare Bioscience, up from -$585852.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.3 million in Q4 2023 and bottomed at -$585852.0 in Q3 2024.
  • Average Gains from Investment Securities over 4 years is $184567.4, with a median of $81373.0 recorded in 2022.
  • Peak annual rise in Gains from Investment Securities hit 289.49% in 2023, while the deepest fall reached 4283.92% in 2023.
  • Year by year, Gains from Investment Securities stood at -$329406.0 in 2021, then skyrocketed by 305.71% to $677632.0 in 2022, then skyrocketed by 90.58% to $1.3 million in 2023, then dropped by 25.79% to $958315.0 in 2024.
  • Business Quant data shows Gains from Investment Securities for DARE at $958315.0 in Q4 2024, -$585852.0 in Q3 2024, and -$414148.0 in Q2 2024.